Outlet metrics
Global
N/A
Country
N/A
Category
N/A
Articles
-
Jan 22, 2025 |
ccforum.biomedcentral.com | Freiburg im Breisgau |Faculté de Médecine |Nouvel Hôpital Civil
Simon A. Amacher and Caroline E. Gebhard planned and designed the study. Pimrapat Gebert performed the formal statistical analysis of the data provided by the Swiss Society of Intensive Care Medicine and the Federal Statistics Office. Simon A. Amacher, Pimrapat Gebert, and Caroline E. Gebhard interpreted the data. Caroline E. Gebhard and Simon A. Amacher wrote the inaugural draft of the manuscript. Simon A.
-
Jan 15, 2025 |
ccforum.biomedcentral.com | Clinical Applications
This study involved the analysis of prospective cohorts of adult patients with sepsis (n = 53) or septic shock (n = 63) and healthy controls (n = 50) from Zhongda Hospital, as well as pediatric septic patients (n = 88) or septic shock patients (n = 18) and healthy controls (n = 90) from the Children’s Hospital of Nanjing Medical University.
-
Jan 14, 2025 |
ccforum.biomedcentral.com | Fabio Silvio
ReferencesOddo M, Sandroni C, Citerio G, Miroz JP, Horn J, Rundgren M, et al. Quantitative versus standard pupillary light reflex for early prognostication in comatose cardiac arrest patients: an international prospective multicenter double-blinded study. Intensive Care Med. 2018;44(12):2102–11. Article PubMed PubMed Central Google Scholar Oddo M, Taccone FS, Petrosino M, Badenes R, Blandino-Ortiz A, Bouzat P, et al.
-
Jan 12, 2025 |
ccforum.biomedcentral.com | Anna Conway
An acute, unexpected ICU admission, especially in the presence of prognostic uncertainty, is a challenging, threatening, or aversive situation, a potential stressor [10]. This traumatic event which will affect each family member differently, depending on individual characteristics, type and characteristics of the event(s), developmental processes, the meaning attached to the trauma, and sociocultural factors [11].
-
Jan 12, 2025 |
ccforum.biomedcentral.com | Liver Diseases
This was a single-center, randomized, double-blind, placebo-controlled, phase 2 trial of inulin for the purpose of preventing gut pathogen colonization and infection in the ICU. Patients were randomized 1:1:1 to placebo, inulin 16 g/day, or inulin 32 g/day beginning on October 14, 2019. Prior to enrollment of the first patient, a data and safety monitoring board (DSMB) was appointed which had full access to the study data.
Contact details
No sites or socials found.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →